Skip to main content
. 2020 Mar 25;12(4):297. doi: 10.3390/pharmaceutics12040297

Figure 5.

Figure 5

Recovery time in a typical patient following the omission of the IR (A) and XR (B) formulation doses; and relative frequency of recovery times in patients on both formulations (C). p-value of the Kolmogorov–Smirnov test is shown in panel (C).